Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Farrell

Showing results (1-10 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Gastroenterology|January 24, 2013
Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?David J Farrell
Annals of Clinical Microbiology and Antimicrobials|August 19, 2007
Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese childrenKeisuke Sunakawa, David J Farrell
Antimicrobial Agents and Chemotherapy|April 24, 2004
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003David J Farrell, David Felmingham
The Journal of Antimicrobial Chemotherapy|August 11, 2005
The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniaeDavid J Farrell, David Felmingham
The Journal of Antimicrobial Chemotherapy|July 22, 2004
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002David J Farrell, Stephen G Jenkins
Gerontology & Geriatric Medicine|January 24, 2022
COVID-19 Across the Landscape of Long-Term Care in Alameda County: Heterogeneity and DisparitiesTerry E Hill, David J Farrell
The Journal of Antimicrobial Chemotherapy|July 22, 2004
Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002Steven D Brown, David J Farrell
Gerontology & Geriatric Medicine|February 28, 2022
A Typology of COVID-19 Data Gaps and Noise From Long-Term Care Facilities: Approximating the True NumbersTerry E Hill, David J Farrell
Emerging Infectious Diseases|September 16, 2009
Increase in pneumococcus macrolide resistance, United StatesStephen G Jenkins, David J Farrell
International Journal of Antimicrobial Agents|January 8, 2008
Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004)David J Farrell, Catherine Couturier, Waleria Hryniewicz
Pageof 18

Showing results (1-10 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Gastroenterology|January 24, 2013
Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?David J Farrell
Annals of Clinical Microbiology and Antimicrobials|August 19, 2007
Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese childrenKeisuke Sunakawa, David J Farrell
Antimicrobial Agents and Chemotherapy|April 24, 2004
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003David J Farrell, David Felmingham
The Journal of Antimicrobial Chemotherapy|August 11, 2005
The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniaeDavid J Farrell, David Felmingham
The Journal of Antimicrobial Chemotherapy|July 22, 2004
Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002David J Farrell, Stephen G Jenkins
Gerontology & Geriatric Medicine|January 24, 2022
COVID-19 Across the Landscape of Long-Term Care in Alameda County: Heterogeneity and DisparitiesTerry E Hill, David J Farrell
The Journal of Antimicrobial Chemotherapy|July 22, 2004
Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002Steven D Brown, David J Farrell
Gerontology & Geriatric Medicine|February 28, 2022
A Typology of COVID-19 Data Gaps and Noise From Long-Term Care Facilities: Approximating the True NumbersTerry E Hill, David J Farrell
Emerging Infectious Diseases|September 16, 2009
Increase in pneumococcus macrolide resistance, United StatesStephen G Jenkins, David J Farrell
International Journal of Antimicrobial Agents|January 8, 2008
Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004)David J Farrell, Catherine Couturier, Waleria Hryniewicz
Pageof 18